3Kiyose S, Igarashi H, Nagura K, et al. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immuno- histoehemistry (IHC) and fluorescence in situ hybridization (FISI-I)[J]. Pathol Int,2012,62(11) :728-734.
4Broom RJ, Tang PA, Simmons C, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer[J]. Anticancer Res,2009,29(5):1557-1562.
5Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management[J]. Oncologist, 2008,13 (8) : 838-844.
6Falek AK, Fern6 M, Bendahl PO, et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer [J].World J Surg, 2010,34(7) : 1434-1441.
8Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice[J]? Ann Oncol, 2011,22 (10) : 2227-2233.
9Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast caneer[J]. Ann Oneol, 2009, 20 (12) : 1953-1958.
10Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis[J]. Ann Oncol, 3013,24(1) : 101-108.
